Methods for treating attention deficit hyperactivity disorder

• US 9,907,803 B2
• Filed: 10/04/2016
• Issued: 03/06/2018
• Est. Priority Date: 04/08/2014
• Status: Active Grant

• Current Assignee: Reviva Pharmaceuticals, Inc.
• Original Assignee: Reviva Pharmaceuticals, Inc.
• Inventors: Bhat, Laxminarayan
• Primary Examiner(s): CHONG, YONG SOO
• Application Number:
  US15/284,826
• Publication Number:
  US 20170035772A1
• Time in Patent Office: 518 Days
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 31/5355 Non-condensed oxazines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Claims

1. A method of treating attention deficit hyperactivity disorder (ADHD), the method comprising administering to a patient in need thereof an effective amount of a compound of Formula 1:

2. The method according to claim 1, wherein R³, R⁴, R⁶, R⁷, and R⁸ are hydrogen.

3. The method according to claim 1, wherein R⁴ is H.

4. The method according to claim 1, wherein R¹ and R² are independently H, halogen, or alkoxy.

5. The method according to claim 4, wherein R¹ is H, and R² is methoxy.

6. The method according to claim 1, wherein R¹ and R² are chloro.

7. The method according to claim 1, wherein A is —

O—

(CH₂)_n—

; and

R³, R⁴, R⁶, R⁷, and R⁸ are independently hydrogen or alkyl.

8. The method according to claim 7, wherein R³, R⁴, R⁶, R⁷, and R⁸ are hydrogen.

9. The method according to claim 7, wherein R¹ is H, and R² is methoxy.

10. The method according to claim 7, wherein R¹ and R² are chloro.

11. The method according to claim 1, wherein the compound is 6-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3-(4H)-one hydrochloride.

13. The method according to claim 1, wherein the compound is in the form of a hydrochloride salt.

14. The method according to claim 1, wherein the compound is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent.

15. The method according to claim 1, wherein A is —

O—

(CH₂)_n—

, n=2-5;

R³, R⁴, R⁶, R⁷, and R⁸ are H; and

R¹ and R²is independently H, halogen, or alkoxy.

12. A method of treating attention deficit hyperactivity disorder (ADHD), comprising administering to a patient in need thereof an effective amount of

6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride, or a pharmaceutically acceptable salt, isomer, racemate, or diastereomeric mixture thereof.